A randomized controlled trial of two chemotherapy regimens — paclitaxel liposome combined with platinum and paclitaxel combined with platinum in concurrent chemoradiotherapy for cervical carcinoma

Zeng, Siyuan; Li, Ling; Zhong, Meiling; Jiang, Wei; Wu, Yunyan; Liu, Yi

doi:10.1007/s10330-011-0901-9

Cited by 3 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the limitations of this retrospective study, the adverse reactions reported in this study were not comprehensively included, such as peripheral neuropathy. In other studies, liposome autophagy significantly reduced allergy, skin rash, gastrointestinal toxicity, bone marrow suppression, muscle/joint pain, and peripheral neuropathy compared with conventional paclitaxel 29,30 …”

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

“…In other studies, liposome autophagy significantly reduced allergy, skin rash, gastrointestinal toxicity, bone marrow suppression, muscle/joint pain, and peripheral neuropathy compared with conventional paclitaxel. 29,30 In this study, we assessed the efficacy evaluation methods of esophagography combined with CT, which can effectively determine patients' prognoses. The 3-year PFS rate of patients who achieved CR was 92.3%, whereas the PFS rate of patients who did not achieve CR was only 15.3%.…”

Section: Toxicitymentioning

confidence: 99%

See 2 more Smart Citations

Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis

Liu

Cui

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Purpose This single‐center retrospective clinical study aimed to evaluate the efficacy and feasibility of chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC). Methods Patients with locally advanced ESCC treated with paclitaxel‐liposome‐based chemoradiotherapy between 2016 and 2019 were retrospectively analyzed. Overall survival (OS) and progression‐free survival (PFS) were evaluated using Kaplan–Meier analysis. Results Thirty‐nine patients with locally advanced ESCC were included in this study. The median follow‐up time was 31.5 months. The median OS time was 38.3 (95% confidence interval [CI]: 32.1–45.1) months, and the 1‐, 2‐, and 3‐year OS rates were 84.6%, 64.1%, and 56.2%, respectively. The median PFS time was 32.1 (95% CI: 25.4–39.0) months, and the 1‐, 2‐, and 3‐year PFS rates were 71.8%, 43.6%, and 43.6%, respectively. The most common Grade IV toxicity was neutropenia (30.8%) followed by lymphopenia (20.5%). There were no cases of Grade III/IV radiation pneumonia, and four patients (10.3%) had Grade III/IV esophagitis. Conclusion Chemoradiotherapy using paclitaxel liposome and cisplatin is a well‐tolerated and effective treatment regimen for locally advanced ESCC.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Toxicitymentioning

confidence: 99%

See 1 more Smart Citation

Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis

Liu

Cui

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…After observation of the eligibility criteria, 19 primary articles were selected, including 16 articles in English and three articles in Chinese (Figure 1). 5,18,20,21,[24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] These articles comprised a total of 5787 participants and six paclitaxel formulations including solvent-based paclitaxel, Nab-P, Lip-P, PM-P, PPX, and PICN. The regimens and dose characteristics of the included studies are presented in Table 2.…”

Section: Resultsmentioning

confidence: 99%

<p>Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis</p>

Chou¹,

Huang²,

Cheng³

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Paclitaxel is wildly used in chemotherapy, however, the adverse drug reactions (ADRs) occurred frequently. Various novel nano-based paclitaxel delivery systems were developed. The aim performed systemically review and meta-analyses to evaluate the effect adverse drug reactions (ADRs) of paclitaxel and its nano-based delivery systems. Methods: Systematically searched PubMed, Embase, Web of Science, Cochrane, Clinicalkey, Clinicaltrial.com, ASCO and ESMO. Data of adverse effect were analyzed to odds ratio (ORs) with 95% confidence interval (CI). The quality of studies was assessed with CASP Randomised Controlled Trial Checklist. Statistical analysis was used WinBUGS software (version 1.4.3) with the NetMetaXL interface (version 1.6.1). Results: Twenty-one studies, including 7011 patients and 6 paclitaxel formulations fulfilled the inclusion criteria. In all grade hypersensitivity reactions, comparing to SB-P, people with Lip-P had 0.19 times (95% CI= 0.02, 1.3) of chance, with Nab-P had 0.47 times (95% CI= 0.11, 1.40) of chance, with PPX had 0.44 times (95% CI= 0.03, 5.7) of chance for all grade adverse effect. In All grad neutropenia, comparing to Lip-P, people with SB-P had 0.83 times (95% CI= 0.15, 4.81) of chance for all grade adverse effect; comparing to PM-P, people with SB-P had 0.73 times (95% CI= 0.22, 2.42) of chance for all grade adverse effect. In leucopenia, comparing to Nab-P, people with SB-P had 0.66 times (95% CI= 0.50, 0.87) of chance for all grade adverse effect; comparing to PM-P, people with SB-P had 0.64 times (95% CI= 0.32, 1.16) of chance for all grade adverse effect. The rate of incidence in peripheral sensory neuropathy, myalgias and arthralgias tend to no significant differences between different formulations. Conclusion: Nano-based paclitaxel delivery resulted in fewer hypersensitivity reactions than solvent-based delivery. However, the incidence of neutropenia and leucopenia was higher in nano-based than solvent-based paclitaxel delivery. Dose-dependent ADRs were more frequent in paclitaxel anticancer treatment.

show abstract

“…In addition, marrow suppression could cause fever, skin rash, bone pain, and other adverse reactions. [ 9 – 11 ] Furthermore, it may lead to treatment interruption or even death. [ 12 , 13 ]…”

Section: Introductionmentioning

confidence: 99%

Acupuncture for the treatment of marrow suppression after chemotherapy

Geng

Yin²,

Sun³

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Cancer continues to be a severe global health problem and the leading cause of death worldwide. Chemotherapy as the main treatment has various side effects, of which marrow suppression is the most common one. Acupuncture had shown clinical effects for marrow suppression after chemotherapy in many studies. However, the efficacy and safety of acupuncture therapy for marrow suppression after chemotherapy remains unclear. Objective: This protocol aims to evaluate the efficacy and safety of acupuncture for marrow suppression after chemotherapy according to the existing randomized controlled trials. Methods and analysis: The randomized controlled trials on acupuncture therapy for marrow suppression after chemotherapy will be searched in the database of Embase, PubMed and Cochrane Library, Allied and Complementary Medicine Database (AMED), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), WanFang Database (WF), and related registration platforms (WHO ICTRP, Clinical Trials, and Chinese Clinical Trial Register [ChiCTR]), Grey Literature Database from inception to 1 August 2020. The primary outcomes will be assessed using white blood cell (WBC) count, platelet count, hemoglobin count and the number of neutrophils (N). Review Manager V.5.3 software will be applied for statistical analyses. We will measure the risk of bias of the included studies with Cochrane Collaboration Risk of Bias Tool. Finally, Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) will be used to grade the overall quality of evidence. And we will use the intra-group correlation coefficient to assess the consistency of reviewers. Result: This systematic review and meta-analysis will put a high-quality synthesis of the efficacy and safety of acupuncture treatment in marrow suppression after chemotherapy. Conclusion: The conclusion of this systematic review will provide evidence to assess acupuncture therapy is an efficacy and safe intervention to treat and control marrow suppression after chemotherapy. PROSPERO registration number: PROSPERO CRD42020163336

show abstract

A randomized controlled trial of two chemotherapy regimens — paclitaxel liposome combined with platinum and paclitaxel combined with platinum in concurrent chemoradiotherapy for cervical carcinoma

Cited by 3 publications

References 2 publications

Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis

Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis

<p>Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis</p>

Acupuncture for the treatment of marrow suppression after chemotherapy

Contact Info

Product

Resources

About